预约演示
Iantrek reports two upcoming American Academy of Ophthalmology presentations of its breakthrough glaucoma surgical technologies, including 1-year results of a novel supraciliary outflow micro-interventional procedure
2023-10-16
临床结果
Iantrek reports two upcoming American Academy of Ophthalmology presentations of its breakthrough glaucoma surgical technologies, including 1-year results of a novel supraciliary outflow micro-interventional procedure
WHITE PLAINS, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Iantrek, Inc. announced today that two of its scientific abstract presentations were accepted by the American Academy of Ophthalmology at the upcoming AAO meeting in San Francisco, CA, November 3-6, 2023. These presentations will highlight the clinical results of its CycloPen supraciliary interventional system for suprachoroidal outflow bio-tissue reinforcement as well as a combined dual-outflow trabecular and supraciliary intervention in Open Angle Glaucoma.
Iantrek continues to validate its innovative MIGS technologies for supraciliary and trabecular outflow enhancement. At AAO 2023, its authorship team comprising of Doctors Sean Ianchulev, Ike Ahmed, Robert Weinreb, Arsham Sheybani, Gautam Kamthan, Farrel C Tyson, Ernesto Calvo, and Lautaro Vera will share 12-month safety and effectiveness data of Iantrek’s CycloPen System for supraciliary intervention with homologous bio-tissue reinforcement. The 12-month results in combination with cataract surgery demonstrated a 42% reduction in IOP from a medicated baseline of 22.6 mmHg to 13.2 mmHg. The mean number of glaucoma medications used was reduced from 1.3 to 0.5. The allograft scaffolding material was well-tolerated with durable and sustained effect.
Iantrek’s second presentation reports on a novel combination MIGS intervention to address both the suprachoroidal and the trabecular outflow. The case series demonstrates surgical feasibility and MIGS-type safety of the dual outflow micro-interventional approach with potentially synergistic effect of the two procedures.
Iantrek is a micro-interventional glaucoma company founded by ophthalmic innovator Sean Ianchulev, MD MPH, Professor of Ophthalmology at New York Eye and Ear of Mount Sinai. Iantrek is developing several next-generation MIGS technologies for dual-outflow enhancement utilizing advanced supraciliary, trabecular and bio-tissue µ-interventions.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-药物
-Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。